The White House said Nov. 3 that prescription drug prices are falling at the fastest rate in more than 60 years, and it pointed to TrumpRx, a government-branded website that lists cash discounts on more than 800 drugs. The claim came in a release that reposted an essay by Dr. Joel Zinberg from City Journal. For retirees, the sweeping claim matters less than a narrower question: how a given prescription gets paid for.
According to the release, prescription drug prices fell 4.5% over the past 12 months, the biggest annual drop since 1963, while overall consumer prices rose 3.7%. Zinberg wrote that the prescription drug price index “has either fallen or been flat every month of 2026.” Those are the administration’s statements, and the release is a promotional document, so each figure deserves a look against federal data.
Cash price or plan price for Medicare enrollees
The decision falls on people with Medicare Part D during open enrollment, which runs Oct. 15 to Dec. 7. Anyone who takes a brand-name drug that TrumpRx lists has two routes: pay the site’s cash price, or run the prescription through the drug plan. The two routes can produce different totals for the year, because only one of them moves the person toward the plan’s spending cap. Before choosing, such a person needs the drug’s cash price, the plan’s copay for it and the amount already spent this year.
Stay ahead of government payment news: Miss an enrollment or claim deadline and the money can be gone. Join the Retirement Money Brief and we’ll send you our 2026 Government Check Reality Tracker as a welcome gift.
Get the Brief + the check tracker →
We may earn a commission from links on this page.
Medicare’s own 2027 guide to what is changing, dated September 2026, addresses this directly. It says that paying through TrumpRx or another discount card instead of using Medicare or other coverage is not creditable coverage and does not count toward the Medicare deductible or the out-of-pocket maximum.
The out-of-pocket limit is where the difference shows up. Medicare.gov lists the Part D limit for 2026 at $2,100 a year. Spending that goes through the plan can build toward that cap, while a cash purchase on a discount site does not. A retiree close to the limit may pay less by staying with the plan, and one who takes a cheap generic far from the limit may come out ahead with the cash price.
What the federal price data shows
The Bureau of Labor Statistics published its September consumer price report on Oct. 14. It shows all items up 3.7% over 12 months, the same overall figure the White House cites, and a 1.2% drop in the prescription drugs index in September alone. The broader group called medical care commodities, which includes prescription drugs, fell 3.3% over the 12 months.
The 4.5% figure for prescription drugs by themselves is the White House’s number. The BLS summary page gives the monthly drop and the wider group’s yearly decline, and both point downward. Medical care as a whole rose 1.5% over the year, so a falling drug index is not a sign that health costs in general are shrinking.
A price index tracks the average movement across a large set of drugs. It does not say what one patient pays, and an average decline can sit beside an increase in the single drug a person takes every month. Anyone with a long list of prescriptions gets a better answer from pricing that list than from a national average.
What TrumpRx lists and what the deals say
TrumpRx’s front page lists the Wegovy pill at $149 a month, the Wegovy pen at $199, Ozempic at $199 and Zepbound at $299, each shown beside a higher original price. The site also advertises hundreds of generics. The page does not say which insurance, if any, can be used with those prices.
The White House release says TrumpRx launched in February 2026 and that agreements with Eli Lilly and Novo Nordisk lower GLP-1 costs for government programs and for TrumpRx buyers. It says the agreements also expand Medicare obesity coverage with a $50 monthly copay. Zinberg notes that fewer than a third of employer plans cover GLP-1 drugs for obesity.
Spending on those drugs is large. Zinberg puts 2025 U.S. prescription spending on tirzepatide, sold as Zepbound and Mounjaro, and on semaglutide, sold as Ozempic and Wegovy, at roughly $60 billion each. A price cut on drugs with that much spending can weigh heavily on a national average.
Projections that travel with the claim
A White House fact sheet from Sept. 18 adds projections: nearly $65 billion in Medicaid drug savings over the next decade from most-favored-nation pricing, and savings above $600 billion from agreements with 26 drugmakers that cover 90% of the branded U.S. market. Both are White House projections, not measured results.
The same Sept. 18 fact sheet says GLP-1 drugs that once cost more than $1,000 a month start as low as $149 on TrumpRx, and that eligible Medicare seniors pay $50 a month. It does not name the Medicare program or give a start date, so retirees hoping to use that $50 price should ask their plan before counting on it.
The two claims, falling prices and low cash prices, are separate. Prices can fall on the index while one retiree’s drug stays expensive, and a low cash price can be the best route for a drug the plan covers poorly. Which one applies depends on the drug, the pharmacy and where the person stands against the Part D cap.
The plan choice carries a firm date, Dec. 7. The cash-price comparison has no such date, but it is worth making before then, since the plan’s drug list and copays for 2027 are what decide whether the cash route is ever the better one.
Filling the prescription through the plan or a cash site?
Open enrollment ends Dec. 7, and the plan chosen by then sets the copays and the deductible for 2027. A retiree who takes a drug that TrumpRx lists at a cash price can lose track of which route counts toward the cap, and Medicare says the discount-site route does not.
Cut Your Medicare Bill walks through the fall plan check by total yearly cost, the $2,100 drug cap for 2026 and what counts toward it, and the 2026 Medicare costs at a glance on one table. It is a guide to the pricing, not a plan recommendation.
Inside is a worksheet for the fall plan check, built so a retiree can line up each prescription against each plan’s yearly total, plus a large-print edition.
Get the Medicare cost table and drug-cap guide →
This article was produced with AI assistance and edited for accuracy against the sources linked above.